https://scholars.lib.ntu.edu.tw/handle/123456789/560358
標題: | Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations | 作者: | YI-HSIN LIANG Lin Y.-L. JAU-YU LIAU JIA-HUEI TSAI JIN-TUNG LIANG BEEN-REN LIN JI-SHIANG HUNG LI-HUI TSENG LIANG-IN LIN YIH-LEONG CHANG ANN-LII CHENG KUN-HUEI YEH |
公開日期: | 2015 | 出版社: | International Institute of Anticancer Research | 卷: | 35 | 期: | 7 | 起(迄)頁: | 4207-4214 | 來源出版物: | Anticancer Research | 摘要: | Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear. Patients and Methods: This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011. Results: The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC. Conclusion: Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937110854&partnerID=40&md5=e284866c2bb291365cc8d31b27b6eb69 https://scholars.lib.ntu.edu.tw/handle/123456789/560358 |
ISSN: | 0250-7005 | SDG/關鍵字: | bevacizumab; cetuximab; fluorouracil; irinotecan; K ras protein; oxaliplatin; antineoplastic agent; cetuximab; codon; KRAS protein, human; monoclonal antibody; oncoprotein; Ras protein; adult; aged; Article; cancer prognosis; cancer staging; cancer survival; codon; comparative study; female; follow up; gene mutation; groups by age; human; major clinical study; male; metastatic colorectal cancer; monotherapy; overall survival; priority journal; retrospective study; sex difference; statistical significance; tumor localization; codon; Colorectal Neoplasms; genetics; metastasis; middle aged; mutation; prognosis; Taiwan; very elderly; young adult; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Codon; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; ras Proteins; Retrospective Studies; Taiwan; Young Adult |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。